Otsuka Pakistan Limited

OTSU

PK0038001019

Pharmaceuticals

End-of-day quote Pakistan S.E. Other stock markets 18:00:00 2024-07-01 EDT			5-day change	1st Jan Change
116 ^PKR	+0.35%		-0.87%	-17.02%

04-30	Otsuka Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	CI
02-29	Otsuka Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	CI

Otsuka Pakistan Limited Announces Director Changes with Effect from August 28, 2018

August 27, 2018

Otsuka Pakistan Limited announced resignation of Hakugi Kiyono as director and appointment of Daisuke Hashimoto as director with effect from August 28, 2018.

Latest news about Otsuka Pakistan Limited

Otsuka Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	04-29	CI
Otsuka Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	02-29	CI
Otsuka Pakistan Limited Announces Board Changes	02-27	CI
Otsuka Pakistan Limited Announces Chief Executive Officer Changes	02-26	CI
Otsuka Pakistan Limited Reports Earnings Results for the First Quarter Ended September 30, 2023	23-10-31	CI
Otsuka Pakistan Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-28	CI
Otsuka Pakistan Limited Approves Executive Changes	23-08-25	CI
Otsuka Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-04-28	CI
Otsuka Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23-03-01	CI
Otsuka Pakistan Limited Reports Earnings Results for the First Quarter Ended September 30, 2022	22-10-31	CI
Otsuka Pakistan Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-09-09	CI
Otsuka Pakistan Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-09-08	CI
Otsuka Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022	22-04-28	CI
Otsuka Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021	22-03-04	CI
Otsuka Pakistan Limited Announces Board Appointments	21-11-02	CI
Otsuka Pakistan Limited Reports Earnings Results for the First Quarter Ended September 30, 2021	21-10-27	CI
Otsuka Pakistan Limited Reports Earnings Results for the Full Year Ended June 30, 2021	21-08-31	CI
Otsuka Pakistan Limited Announces Final Cash Dividend for the Year Ended June 30, 2021	21-08-31	CI
Otsuka Pakistan Limited Reports Earnings Results for the Third Quarter Ended March 31, 2021	21-04-27	CI
Otsuka Pakistan Limited Announces Appointment of Chief Executive Officer of Otsuka Pakistan Limited	21-03-03	CI
Otsuka Pakistan Limited Reports Earnings Results for the Second Quarter Ended December 31, 2020	21-02-25	CI
Otsuka Pakistan Limited Reports Earnings Results for the First Quarter Ended September 30, 2020	20-10-22	CI
Otsuka Pakistan Limited Reports Earnings Results for the Full Year Ended June 30, 2020	20-09-01	CI
Shanghai MicroPort Medical Co., Ltd. Enters into the Agreement with Otsuka Pakistan Limited	20-04-26	CI
Otsuka Pakistan Limited Reports Earnings Results for the Third Quarter Ended March 31, 2020	20-04-22	CI

Otsuka Pakistan Limited is a Pakistan-based company engaged in the manufacturing, marketing and distribution of intravenous (IV) infusions and trading in pharmaceutical products, nutritional foods, and medical equipment. It is primarily focused on IV solutions and has a range of electrolyte solutions, carbohydrate solutions, and clinical nutrition products. Its products include intravenous solutions, medical devices, clinical nutrition, therapeutic drugs and nutraceutical products. Its intravenous solutions include electrolyte solutions, standard solutions, ampoules, OTSUZOL, OTSUMOL infusion, and others. Its medical devices include urea breath test (UBT), Plasline solution, EUCATECH and Support C. Its clinical nutrition products include Aminoleban Oral, AMINOVEL 600, PAN-AMIN G, and AMINOLEBAN INJECTION. Its therapeutic drugs include Pletaal and Mucosta. Its nutraceutical products include ORTie, which is a special combination of dry salts and vitamin C to be mixed with safe water.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
OTSUKA PAKISTAN LIMITED	-17.02%	5.04M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+21.80%	43.81B
OTSUKA HOLDINGS CO., LTD.	+30.40%	23.03B
SANDOZ GROUP AG	+20.03%	15.45B
CIPLA LIMITED	+19.05%	14.4B
ZYDUS LIFESCIENCES LIMITED	+58.92%	12.95B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-11.84%	6.49B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+13.00%	5.49B